Consistently, the ACSL4 inhibitor rosiglitazone also had kidney protective effects against IRI-induced AKI by reducing the infiltration of immune cells and ferroptotic cell death [48, 151]. This evidence concerns the gene ACSL4 and acute kidney injury.